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Abstract. Mutations in progranulin gene (GRN) are a common cause of autosomal dominant frontotemporal lobar degeneration
and are associated with a wide phenotypic heterogeneity. Here, we describe two probands with behavioral variant frontotemporal
dementia with a novel mutation in this gene (1159 1160delTG). Both had a positive family history for dementia and showed
atypical features at imaging. Their progranulin plasma levels were undetectable, and the mutation was not present in cDNA,
suggesting haploinsufficiency. Progranulin levels were low even in asymptomatic carriers of the variant. Results described
enlarge current knowledge on genetic causes of the disease and clinical characteristics of carriers.
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INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is rec-
ognized as one of the more common type of presenile
dementia, accounting for 8–10% of all dementia
patients [1], with a prevalence of about 4–15 cases
per 100,000 [2]. The disease manifests with different
clinical syndromes: behavioral variant (bvFTD) and
two syndromes affecting mainly the language, seman-
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tic dementia (SD) and progressive non-fluent aphasia
(PNFA). There is a familial history in nearly one third
to a half of the cases, where it is possible to recog-
nize an autosomal dominant pattern of inheritance [3].
To date, there are three main genetic causes of famil-
ial FTLD: Microtubule Associated Protein Tau gene
(MAPT), progranulin (GRN), both located on chro-
mosome 17, and the hexanucleotide repeat expansion
in the Open Reading Frame 72 gene in chromo-
some 9 (C9ORF72). The pathology includes two main
patterns: tau deposition (FTLD-Tau), which is typi-
cally found in subjects carrying MAPT mutations, and
immunoreactivity for ubiquitin (FTLD-U). The latter
is split in different entities depending on the major
protein present. TAR DNA binding Protein (TDP)-43
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is found in the majority of the non-tau pathological
pattern, including GRN and C9ORF72 mutated sub-
jects (see [4] for review).
GRN mutations are found in 5–20% of FTLD famil-
ial cases and 1–5% of sporadic cases [5]. The gene is
located on chromosome 17q21 and is composed by 13
exons encoding for progranulin, a cysteine-rich growth
factor which is secreted and cleaved in several frag-
ments (granulins). It is expressed in multiple tissues
of the body and it has pleiotropic actions, including
functions related to neural proliferation, survival, and
inflammation.
The majority of genetic defects in GRN are loss-
of-function mutations, causing haploinsufficiency, and
are associated with extremely low plasma progran-
ulin levels [6, 7]. The penetrance of GRN mutations
is incomplete and this condition is probably due to
the presence of other genes influencing the manifesta-
tion of the disease. In this regard, TransMEMbrane
(TMEM)106B, coding for a transmembrane protein
that associate with progranulin in endo-lysosomes, has
been recently identified as a disease modifier in GRN
mutation carriers [8].
The clinical presentation associated withGRNmuta-
tions is extremely heterogeneous in terms of symptoms,
disease duration, and age of onset. Patients usually
present with any of the defined syndromes of FTLD,
but in some cases there is prominent involvement of
the extrapyramidal and motor systems, showing a clin-
ical picture of a corticobasal syndrome, supranuclear
palsy, or FTD with motor neuron disorders [9]. Typ-
ical neuroimaging in GRN mutation carriers consists
of asymmetric brain atrophy with additional features
such as asymmetric damage to white matter, severe cor-
tical atrophy, and parietal lobe involvement. Here, we
describe two families with a novel mutation in GRN.
Probands, both with positive family history for demen-
tia, developed FTD and showed very low plasma levels
and atypical imaging features.
CASE REPORTS
Patient #1
According to his relatives, Patient #1 developed mild
language deficits together with disinhibition and apa-
thy at the age of 68. One year later, he showed cognitive
decline, markedly altered behavior, and a reduced func-
tion in daily-working activities. In addition, he man-
ifested sleep disturbances, visual disperceptions and
falls, requiring access to the emergency department,
from which he was directed to our Neurology unit.
1:1
II:1*
III:1* III:2*
*Underwent genetic testing
III:3*
II:2
III:4
II:3*
II:3 I:4
II:4*
I:2
Fig. 1. Pedigree of patient #1 (arrow). Square indicate males, cir-
cles females; diamonds are used instead to avoid disclosing sex in
non-affected individuals. Black indicates symptomatic subjects, gray
presymptomatic, and white asymptomatic. Bars indicate deceased
family members.
His family history was positive for dementia, as
his mother and maternal aunt were diagnosed with
dementia in their seventies (Alzheimer’s disease and
Lewy body dementia, respectively) (Fig. 1, I:2, I:3).
The collection of anamnestic information revealed
arterial hypertension, arterial vasculopathy with
femoral and carotid stenosis, dyslipidemia, obstruc-
tion sleep apnea syndrome, and prostatic hypertrophy.
During the medical evaluation, he showed disinhib-
ited behavior and lack of attention. In addition, sexual
disinhibition and hyperorality were reported by his
wife. The neurological examination was unremark-
able, except for the evidence of primitive reflexes
and an initial mild gait ataxia, whereas no language
impairment was observed. At neuropsychological test-
ing, the patient scored 28/30 on MMSE (normal
memory, language, and visuo-spatial functions) show-
ing global efficiency in cognition associated with
behavioral disturbances, disinhibition, and poor social
judgment. Furthermore, the patient history outlined an
insufficient performance in daily self-care activities
(ADL = 5/6, IADL = 2/8).
Axial T1-weighted scans at the magnetic reso-
nance imaging (MRI) showed asymmetric frontal
and temporal cortical atrophy (right > left) (Fig. 2A).
The coronal T1-weighted scan documented asym-
metric temporal atrophy (right > left) (Fig. 1C).
[18F]-Fludeoxyglucose positron emission tomography
(FDG-PET) showed bilateral frontal and temporal
hypometabolism (Fig. 2B). Cerebrospinal fluid (CSF)
biomarkers were normal (amyloid-= 731 pg/ml;
tau = 181 pg/ml; Ptau = 29 pg/ml). As the patient did
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Fig. 2. MRI of patient #1. A) Axial T1-weighted MRI scan documenting asymmetric frontal cortical atrophy (arrow) and temporal cortical
atrophy (right > left); B) coronal T1-weighted MRI scan documenting asymmetric temporal atrophy (right > left).
Fig. 3. FDG-PET of patient #2, showing areas of hypometabolism mainly on the right side in fronto-temporal regions and thalamus and frontal
cortex and insula (p = 0.001).
not show clinical symptoms and signs suggesting
motor neuron disease, the electromyography was not
carried out.
Patient #2
Patient #2, a male, began presenting with loss of
inhibitory control, relevant mood alterations related to
emotional lability, anedonia, apathy, depressive mood,
anosognosia, and loss of hobbies and personal inter-
ests at the age of 66. The onset of symptoms started
after retirement and they progressively worsened, with
the addition of cognitive deficits of language (anomia,
dysarthria, and stutter), memory and difficulties in
the spatial orientation. He also suffered from mild
dysphagia both for solid and liquid foods. Neuropsy-
chological assessment showed normal global cognitive
profile (MMSE 28/30) with partially reduced daily-
living activities (ADL 5/6, IADL 4/5) and scores under
the normality threshold in praxis and attention. He
suffered from hypertension and extrapyramidal signs
lateralized on the left side. His family history was
positive for FTD (father and sister). Electromyog-
raphy and magnetic evoked potentials were normal,
while brain CT showed bilateral temporal ventricu-
lar atrophy. The patients refused the lumbar puncture
and MRI examination. Brain FDG-PET, using SPM5
software (Supplementary Materials), showed areas of
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Fig. 4. Electropherogram of the DNA (top) and cDNA (bottom).
hypometabolism mainly on the right side in frontotem-
poral regions and thalamus, in bilateral superior frontal
gyrus and left insula (p = 0.001) (Fig. 3).
METHODS AND RESULTS
Both patients met the criteria for bvFTD [10]. In
both probands, progranulin plasma levels, evaluated
through an ELISA kit (Adipogene, Korea) after the
ethical committee approval and patients’ consent, were
below the detection threshold (<15 ng/ml).
Therefore, we sequenced (GRN) and found a novel
mutation in exon 5: g.1159 1160delTG, that leads
to a frameshift, which in turn creates a stop codon
(c.445 446delTG, p.Cys 149fsX10).
The mutation was not observed in the cDNA isolated
from peripheral blood cells, thus confirming that the
aberrant mRNA is degraded through nonsense medi-
ated decay (Fig. 4).
Additional family members of Patient #1 were
asymptomatic carriers of the mutation (Fig. 1A, III:2
and II:3 age 37 and 50 years, respectively). Both of
them had plasma progranulin levels under the detec-
tion threshold (61 pg/ml) [11], whereas subjects III:1
and II:4, who did not carry the mutation, had normal
progranulin plasma levels. Relatives of patient #2 did
not give informed consent for blood collection.
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DISCUSSION
Here, we described two patients with FTD carrying
a novel mutation in GRN. Both families originate from
the same region (central Italy), suggesting that they
could derive from the same founder. Nevertheless, we
did not have a large population to carry out a haplotype
analysis.
So far, 69 different pathogenic mutations in GRN
have been described, including about ten dinu-
cleotide deletions (http://www.molgen.vib-ua.be). The
most common associated clinical phenotype is FTD,
although corticobasal syndrome has been reported
as well [12]. Regarding patients we described, both
of them showed a typical behavioral syndrome, but
patient #1 developed, in addition, visual disperceptions
and falls. Notably, his aunt was diagnosed with Lewy
body dementia more than ten years before, due to the
development of dementia, falls, and hallucinations, and
died a few years later.
Progranulin plasma levels were undetectable, even
in presymptomatic carriers, suggesting that biologi-
cal changes associated with the mutation occur soon
before clinical manifestations of the disease, and
supporting the hypothesis that plasma progranulin
evaluation could be a very good biomarker for identify-
ing potential carriers. In accordance with MRI data on
other GRN mutation carriers, this new variant showed
asymmetrical atrophy (see [13] for review). In spite
of the marked atrophy, CSF biomarkers were normal,
including tau protein, which is supposed to reflect the
degree of neurodegeneration. This observation is in
line with previous data [14] and suggests cautious-
ness in the interpretation of an apparently normal CSF
picture.
In conclusion, although further studied on other
family members will be needed to demonstrate the
segregation of the genetic defect with the disease,
the evidence of very low plasma progranulin levels
together with the mRNA nonsense mediated decay
strongly support the hypothesis that the variant is
pathogenic and cause haploinsufficiency.
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